Literature DB >> 3076387

Selective depletion of marrow-T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone-marrow transplantation.

D Maraninchi1, C Mawas, D Guyotat, J Reiffers, J P Vernant, N Gratecos, J Hirn, G Novakovitch.   

Abstract

In vitro depletion of mature pan-T lymphocytes has been widely and successfully used to prevent acute graft-versus-host disease (GVHD) after allogeneic bone-marrow transplantation (BMT). However, this procedure has been associated with a high incidence of graft failure and leukemic relapse. In this pilot study, we evaluated the efficiency of a selective depletion of human marrow T cytotoxic lymphocytes (CD8), a subset essential to induce GVHD in mice. Eleven patients with hematologic malignancies were included (7 HLA-matched BMT, 4 HLA-mismatched BMT). Marrow treatment with 7 anti-CD8 mAbs and rabbit complement resulted in a marked reduction of CD8+ lymphocytes from 15% (median value; range 7%-31%) to 1% (median value; range less than 1%-11%). Acute GVHD was not abolished by this procedure despite postgraft immunosuppression. One patient (HLA-mismatched BMT) rejected his graft and had a full autologous recovery. In conclusion, when compared to the data in the literature, CD8 depletion was shown to be less efficient than pan-T-cell depletion in the prevention of GVHD after allogeneic BMT and was still associated with a major complication associated with this procedure, i.e., graft failure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076387     DOI: 10.1007/bf00353826

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  3 in total

1.  T lymphocytes expressing HECA-452 epitope are present in cutaneous acute graft-versus-host disease and erythema multiforme, but not in acute graft-versus-host disease in gut organs.

Authors:  R E Davis; B R Smoller
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

Review 2.  T cell depletion in paediatric stem cell transplantation.

Authors:  C Booth; P Veys
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

3.  Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib.

Authors:  Naoko Okiyama; Yasuko Furumoto; Vadim A Villarroel; Jay T Linton; Wanxia L Tsai; Jan Gutermuth; Kamran Ghoreschi; Massimo Gadina; John J O'Shea; Stephen I Katz
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.